Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07410117 · ClinicalTrials.gov registry record · Phase 3
REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis
A Phase 3 study of Cancer-Associated Thrombosis (CAT), sponsored by Regeneron Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 860
- Enrollment target
- 5
- Study locations
NCT07410117 is a Phase 3 study of Cancer-Associated Thrombosis (CAT) that is actively recruiting participants, run by Regeneron Pharmaceuticals. The registered enrollment target is 860 participants. The trial reports 5 study locations across 4 states.
The verdict
NCT07410117, a Phase 3 study of Cancer-Associated Thrombosis (CAT), is actively recruiting participants, sponsored by Regeneron Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 860 participants
- Enrollment target
- 5
- Study locations
Study Summary
This study is researching an experimental drug called REGN7508 (called "study drug"). The study is focused on the prevention of Cancer-Associated Thrombosis (CAT) in participants. The aim of the study is to see how effective the study drug is in preventing blood clots in participants with solid tumors who are currently receiving anticancer treatment or planning to start anticancer treatment within a month of being assigned to a study treatment, or recovering from surgery, and how the study drug compares to placebo for CAT. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)
Conditions Studied
Interventions
- DRUG Placebo
- DRUG REGN7508
Study Locations (5)
Other
- Llc Todua Clinic - Tbilisi
- Tbilisi State Medical University and Ingorokva High Medical Technology University Clinic - Tbilisi
Florida
- Bioresearch Partner- Hialeah Hospital - Hialeah
Texas
- El Paso Medical Research Institute (Medresearch Inc) - El Paso
Adjara
- LTD High Technology Hospital Medcenter - Batumi
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 860 participants |
| Start Date | 2026-03-09 |
| Est. Completion | 2030-05-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07410117
The ClinicalTrials.gov registry entry for NCT07410117 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 860 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cancer-Associated Thrombosis (CAT) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07410117 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Other, Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT07410117 about?
NCT07410117 is a clinical study titled "REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis". This study is researching an experimental drug called REGN7508 (called "study drug"). The study is focused on the prevention of Cancer-Associated Thrombosis (CAT) in participants. The aim of the study is to see how effective the study drug is in preventing blood clots in participants with solid tum...
What is the current status of trial NCT07410117?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 860 participants. The study started on 2026-03-09. Estimated completion is 2030-05-06.
What conditions does trial NCT07410117 study?
This clinical trial studies the following conditions: Cancer-Associated Thrombosis (CAT).
What interventions are being tested in trial NCT07410117?
The interventions under investigation include: Placebo (DRUG), REGN7508 (DRUG).
Who is sponsoring clinical trial NCT07410117?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07410117 being conducted?
This trial has 5 study locations across Florida, Texas, Adjara. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.